Korea and India Chart Different Paths to Scale Healthcare AI

Picture a rural clinic where the nearest radiologist is hours away, or an ambulance crew racing toward a hospital that has no idea what's coming through the door. These are the kinds of gaps that healthcare AI promises to close. But promises only matter if the systems around them, the data, the funding, the rules, actually work. Two countries this month offered a study in contrasts on how to get there.

South Korea has moved from talk to action. Last month, the government approved its AI Basic Healthcare Strategy, a sweeping plan to weave AI into primary care, emergency response and hospital systems nationwide. India, meanwhile, is still assessing what's missing. A new industry paper released in New Delhi lays out the gaps that keep AI tools stuck in pilot programs rather than everyday clinical use.

Both countries face the same underlying challenge. Good AI needs good infrastructure beneath it: reliable data, clear rules, and a way to pay for what actually works. How each nation is tackling that challenge reveals a lot about where healthcare AI is headed globally.

Korea's Build-Out, Piece by Piece

South Korea's strategy reads less like a policy document and more like a construction blueprint. At its center is something called the Public Healthcare AI Highway, a network that will link 72 designated medical institutions to a national, GPU-powered AI platform. Think of it as laying digital plumbing so hospitals across the country can tap into the same computing power and shared tools, rather than each building its own system from scratch.

The rollout is staged carefully. Nine institutions join the pilot in the second half of 2026. That grows to 30 by 2027, then all 72 by 2029. It's a slow, deliberate scale-up, the kind that lets policymakers catch problems early rather than after a nationwide launch.

Underpinning all of this will be a National Health and Medical Data Hub, designed to combine health data currently scattered across different institutions. Fragmented data is one of the biggest obstacles to AI in healthcare anywhere in the world. If a hospital's AI tool can only see part of a patient's history, it can only offer part of an answer. Korea's hub is meant to fix that by giving its planned sovereign AI model, a homegrown alternative to relying on foreign AI systems, the fuller picture it needs. Development work begins next year, initially serving regional public hospitals.

The strategy also gets specific about what patients and clinicians will actually see. Public primary care facilities will receive AI packages covering medical imaging, clinical documentation and chronic disease management, tools meant to lighten the load on overworked doctors and catch problems earlier. Remote care pilots will target medically underserved areas, extending expertise to places that have long gone without it. And in Daegu, an integrated emergency AI platform will pilot real-time coordination for ambulance transfers, potentially shaving critical minutes off response times when they matter most.

There's also a patient-facing piece. Korea plans a National AI Health Assistant that translates prescriptions and screening results into plain language, alongside personalized health guidance drawn from a patient's own records. Anyone who has left a doctor's office confused about their own test results will recognize the value here. Complex medical information, made understandable, is its own kind of public health intervention.

Beyond direct care, the country is investing in AI for drug discovery too, through the K-AI Drug Discovery Platform and a separate GPU-based development platform. A national biomedical database covering 120,000 people is expected in the second half of 2026, scaling to more than 700,000 by 2029 and past a million by 2032. That kind of data pool could accelerate research into diseases that currently lack good treatments.

Money and oversight round out the plan. Korea is weighing new reimbursement models that pay for outcomes AI helps deliver, not just for using a given AI product, a subtle but important shift that rewards results over adoption for its own sake. New ethics guidelines and legislation on data privacy and oversight are also planned, alongside investment in regional hospitals to modernize aging IT systems and build AI-specialized care.

India's story looks different. An industry paper prepared by Praxis Global Alliance and the Federation of Indian Chambers of Commerce and Industry, released by Health and Family Welfare Minister J.P. Nadda last month, takes stock of where the country stands. The verdict: foundations exist, through programs like the Ayushman Bharat Digital Mission and the IndiaAI Mission, but the ecosystem needed to move AI from successful pilots into routine clinical care is not yet there.

The paper points to three specific gaps. First, AI-ready health data and evidence are lacking, meaning the raw material AI needs to learn and prove itself is either missing or hard to access. Second, regulation hasn't caught up to the full lifecycle of an AI product, from development through deployment and monitoring. Third, procurement and reimbursement systems don't yet recognize the value AI-enabled tools can add, which makes it hard for hospitals and clinics to justify paying for them.

None of this negates the progress already made. Digital infrastructure has advanced, innovation is happening, and clinicians appear willing to accept these tools. But willingness alone doesn't scale a technology. Fragmented data and thin reimbursement pathways still act as a ceiling on what's possible.

The paper singles out medtech, particularly AI-enabled diagnostics, as one of India's most immediate opportunities. Extending specialist-level diagnostic support into primary and secondary care could ease disparities in access that have long plagued rural and underserved communities. It's a similar logic to Korea's remote care pilots: use AI to bring expertise to places that don't have enough of it.

India's strengths are real. Strong software talent, growing digital public infrastructure, a diverse patient population for clinical research, and an expanding medical device manufacturing base all give the country a plausible path toward becoming a global hub for responsible AI-enabled medical technology. Getting there, the paper stresses, will require real coordination between government, regulators, providers, payers, industry and academia. That's a lot of stakeholders to align, and alignment rarely happens on its own.

Why It Matters

These two approaches matter well beyond Seoul and New Delhi. Korea is essentially testing whether a centrally coordinated, infrastructure-first strategy can move AI from scattered pilots to national scale without leaving smaller hospitals behind. India is testing something else: whether a country with genuine tech and manufacturing strength can build the regulatory and financial scaffolding fast enough to keep pace with its own innovation. Both paths carry risk. Move too fast on data-sharing and you risk privacy and trust. Move too slowly on reimbursement and promising tools never reach the patients who need them. How these two nations navigate that balance will offer real lessons for every health system still trying to figure out where AI actually belongs in patient care.